Clinical trials
PD-1 clinical trials
Below are recruiting pd-1 clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06195228RecruitingPhase 4
Real-world study of genetic types in advanced thyroid cancer
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Fuzhou, FujianAges Any age - NCT05593458RecruitingPhase 3
Stomach cancer surgery before chemo: artery-based or drip chemo
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
Hangzhou, ZhejiangAges 18–75 - NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06417892Recruiting
Fruquintinib combo with or without immunotherapy for stomach cancer
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06385730RecruitingPhase 2
PD-1 blocker before surgery for elderly esophageal cancer
This trial tests a drug (PD-1 blocker) given before surgery for people over 75 with esophageal cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 76 years+ - NCT07555678RecruitingPhase 2
Chemotherapy, radiation, and immunotherapy for anal cancer
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05430698RecruitingPhase 2
PD-1 antibody after surgery for bile duct cancer
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Guangzhou, GuangdongAges 18–75 - NCT07729956RecruitingPhase 3
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07007182RecruitingPhase 2
Treating stomach cancer spread to lymph nodes with chemo, surgery, and radiation
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06307080Recruiting
Combined ablation and immunotherapy for pancreatic cancer with liver spread
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07034391RecruitingPhase 2
PD-1 inhibitor with denosumab and chemo for advanced lung cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
Shenyang, LiaoningAges 18–75 - NCT07625527RecruitingPhase 2
Stopping immunotherapy after bladder cancer disappears
This trial tests whether it's safe to stop immunotherapy once bladder cancer is no longer visible, instead of continuing it for a longer time. It aims to find out if stopping treatment early can reduce side effects while keeping the cancer from coming back.
TianjinAges 18 years+ - NCT04453826RecruitingPhase 3
Test PD-1 plus chemo-radiation for high-risk nasopharyngeal cancer
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT04453813RecruitingPhase 3
Immunotherapy with chemoradiation for recurring nasopharyngeal cancer
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Guangzhou, GuangdongAges 18–70 - NCT04778956RecruitingPhase 3
Toripalimab plus surgery vs surgery alone for recurring throat cancer
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
Guangzhou, GuangdongAges 18–70 - NCT05563012RecruitingPhase 2
Short radiation plus chemo and PD-1 immunotherapy for stomach cancer
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Wuhan, HubeiAges 18–75 - NCT05236972RecruitingPhase 3
PD-1 antibody after colon cancer surgery for dMMR stage III
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
GuangzhouAges 18–75 - NCT05707819Recruiting
Sintilimab plus chemoradiotherapy for high-risk nasopharyngeal cancer
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Nanning, GuangxiAges 18–70 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT05980702RecruitingPhase 2
Comparing 2 vs 4 rounds of chemo-immunotherapy before surgery for head and neck cancer
This trial tests whether 2 or 4 cycles of pembrolizumab (immunotherapy) plus carboplatin and nab-paclitaxel (chemotherapy) before surgery works better for people with advanced head and neck cancer that can be removed. The goal is to see if fewer treatments are just as effective.
Guangzhou, GuangdongAges 18–75 - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70
Hear when a new PD-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-1?
- Yes. Clin2 currently lists 300 recruiting pd-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.